Investor Ideas #Potcasts
526, #Cannabis News and #Stocks on the Move; (TSX.V: $FLWR.V) (OTC: $FLWPF) (Nasdaq: $JAZZ) (Nasdaq: $GWPH) (NYSE: $MJ)
Delta, Kelowna, BC, February 3, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/020321-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/02031FLWR-JAZZ-GWPH-MJ.asp
Hear the investor ideas potcast on Spotify
Hear
Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we will be looking at a few public and private company
announcements.
Dynaleo,
Canada’s highest-capacity manufacturer of premium cannabis-infused soft chews, today
announced the launch of two brands – Sunshower and DYNATHRIVE
CBD. The two new brands are available in authorized retail locations and online
channels in British Columbia and Saskatchewan, with plans to expand to Alberta,
Ontario and additional regions in the near future.
Sunshower will launch with three
delicious flavours (Watermelon Lemonade, Mango Tangerine, and Wild Strawberry)
with each pack containing 5 pieces and 10 mg total THC. Sunshower is aimed at
adults looking for an enjoyable and consistent THC experience with the finest
flavours and ingredients. Inventory in Saskatchewan, the first province to
place orders, has already sold out two shipments in its first month.
DYNATHRIVE CBD is Canada’s first and
only large format CBD soft chew. Our first flavour, Apple Cider Vinegar, is
made with purified CBD isolate, Canadian apple juice and real apple cider
vinegar to deliver a sweetly refreshing, tart taste. The first DYNATHRIVE CBD
format contains 30 pieces, perfect for daily supplements, with 300mg total CBD
and is aimed at the growing segment of wellness consumers who are seeking a
more enjoyable and convenient way to take CBD. The company has also formulated
several additional flavours and unique product formats for launch later in 2021
to compliment these initial offerings.
“We continue to see accelerating
demand in the edibles market for high-quality recreational and wellness
cannabis products, especially from those who want to experience cannabis
without needing to inhale. At the same time, consumers and retailers are
experiencing inconsistent supply, both in terms of quantity and quality. As
Canada’s highest-capacity soft chew manufacturer, we are in a unique position
to have our products available at all times to consistently meet consumer
demand with a best-in-class experience,” says Dynaleo Executive Chairman Michael
Krestell.
Krestell continues, “In terms of the
wellness consumer, countless customers have made it clear that they want CBD
but without the intoxicating effects of THC. The 2- or 5-piece CBD offerings in
the market today do not match up well for customers looking to take CBD on a
daily basis or even throughout the day. The DYNATHRIVE CBD 30-piece pack is the
perfect solution for them.”
The
Flowr Corporation (TSX.V:
FLWR) (OTC:
FLWPF) provided
commentary on the decision by INFARMED, I.P. (“INFARMED”), Portugal’s National Authority of
Medicines and Health Products, to approve the first market authorization which
will allow a licensed producer of medical cannabis to release products in Portugal.
“We applaud the decision by
INFARMED, which was the first of its kind, to allow patients to have access to
medical cannabis products in Portugal through indication-specific market
authorizations. The Portuguese government is forward thinking in its approach
to improving the quality of life for Portuguese patients as scientific data
continues to mount regarding medical cannabis as both safe and efficacious in
treating a variety of conditions,” commented Pauric Duffy, Flowr’s Managing
Director of Europe. “This ground-breaking decision sets the stage for Flowr to
pursue market authorizations to serve Portuguese and European patients with
medical cannabis produced from our world class local facilities in Sintra and
Aljustrel,” commented Lance Emanuel, President and Interim CEO of Flowr.
In March 2020, Flowr announced that
its wholly-owned subsidiary in Europe, Holigen Holdings Limited (“Holigen”),
received its Good Manufacturing Practice (GMP) certification in accordance with
European Union standards, for its indoor manufacturing facility located in
Sintra, Portugal. The GMP certification was issued by INFARMED. Holigen is in
the process of conducting stability testing on certain of its high-THC genetics
and expects results within 2021.
Located just outside of Lisbon,
Holigen’s Sintra facility is a purpose-built facility with six grow rooms, a
research and development lab and an expected extraction processing facility.
The Sintra facility is capable of producing approximately 2,000 kilograms of
premium dried flower when fully optimized. Holigen’s European operations also
include the Aljustrel facility which has more than 5,000,000 square feet of
outdoor grow space and greenhouse capacity, capable of producing in excess of
500,000 kilograms of cannabis when fully operational.
Tikun
Olam Cannbit (TASE:TKUN)
reports that its international arm, Cannabit
Ltd., will
be the exclusive supplier of medical cannabis for
clinical research into treatment for opioid addiction. The company will be
entitled to exclusive marketing of the treatment method in Israel, Germany and
England too.
The study will be done using a
patent for an addiction treatment method that is currently undergoing
registration by JFM Technology Holdings LLC, for which Opiostop has received an
exclusive, unlimited license, under the U.S. FDA's fast-track.
The U.S. company Opiostop will
provide all the financing, the submission of the patent and follow-up
submissions, will be responsible for the performance and financing of the
clinical trial in the United States, and will see to getting all the licenses
for importing into the United States.
The treatment method may affect the
market of opioid sales in the United States, which is estimated at about
$20,000,000,000 (twenty billion dollars) per year.
After his daughter died as a result
of opioid addiction, and his son also became addicted to analgesics, Jonah
Rosenblatt, the founder of Opiostop, developed a special, three-stage method
for withdrawal from opioids. The stages include, among other things, using
approved drugs – synthetic and semisynthetic opioids – combined with treatment
using medical cannabis.
Rosenblatt has already filed a
patent for the method, and the company is now working on raising capital and
starting clinical trials in the United States, with the intent of conducting
clinical trials, submitting and approving the treatment through the FDA's
fast-track.
Avinoam Sapir, the CEO of Tikun
Olam-Cannabit states: "Rosenblatt's opioid method of treatment is on the
FDA's fast-track for approval, in order to solve the problem of severe
addiction to opioids that has been sweeping through the United States in recent
years. Every 17 minutes, someone dies in the United States of an analgesic
overdose. Tikun Olam–Cannabit is happy to be part of the possible solution to
this severe 'plague' of analgesic addiction, a problem that can be identified
here in Israel too."
Jonah Rosenblatt, the CEO of
Opiostop states: "Over 70,000 Americans, and half a million people
worldwide die each year from the Opioid Epidemic. This is ripping apart the
fabric of society. We believe that combining our Multi-modal approach to curing
addiction with CANNBIT'S Cannabinoid based medications & formulations. As
the Clinical research of Medical Cannabis has been shown to reduce opioid
dependency. By coming together in this JV, together we are extremely confident
in our combined effort to reach our goal of giving people back their free will.”
Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today
announced the companies have entered into a definitive agreement
for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the
form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total
consideration of $7.2 billion, or $6.7 billion net of GW cash. The transaction,
which has been unanimously approved by the Boards of Directors of both
companies, is expected to close in the second quarter of 2021.
Upon close of the transaction, the
combined company will be a leader in neuroscience with a global commercial and
operational footprint well positioned to maximize the value of its diversified
portfolio.
GW is a global leader in
discovering, developing, manufacturing and commercializing novel, regulatory
approved therapeutics from its proprietary cannabinoid product platform to
address a broad range of diseases. The company's lead product, Epidiolex®
(cannabidiol) oral solution, is approved in patients one-year and older for the
treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet
Syndrome and Tuberous Sclerosis Complex (TSC), all of which are rare diseases
characterized by severe early-onset epilepsy. Epidiolex was the first plant-derived cannabinoid medicine ever
approved by the U.S. Food and Drug Administration (FDA). This product has also
been approved, under the tradename Epidyolex®, by the European Medicines Agency
(EMA) in patients two years of age and older for the adjunctive treatment of
seizures associated with LGS and Dravet syndrome in conjunction with clobazam
and is under EMA review for the treatment of seizures associated with TSC. In
addition to the approved indications for Epidiolex,
there are considerable opportunities to pursue other indications within the
epilepsy field, including other treatment-resistant epilepsies where
significant unmet needs of patients exist.
Beyond Epidiolex, GW has a scientific platform and deep innovative
pipeline of cannabinoid product candidates, as well as highly specialized
manufacturing expertise, developed over two decades of pioneering and building
leadership in cannabinoid science. This pipeline includes nabiximols, for which
the company is in Phase 3 trials to seek FDA approval for treatment of
spasticity associated with multiple sclerosis and spinal cord injury, as well
as earlier-stage cannabinoid product candidates for autism and schizophrenia.
"Jazz is proud of our
leadership position in sleep medicines and rapidly growing oncology business.
We are excited to add GW's industry-leading cannabinoid platform, innovative
pipeline and products, which will strengthen and broaden our neuroscience portfolio,
further diversify our revenue and drive sustainable, long-term value creation
opportunities," said Bruce Cozadd, chairman and CEO of Jazz
Pharmaceuticals. "We are joining two teams that share a passion for, and
track record of, developing differentiated therapies that advance science and
transform the lives of patients. This will help facilitate a successful
integration and bring added capabilities to Jazz. Given the strength of our
balance sheet and the meaningful financial drivers of the transaction, we are
confident in the value we can deliver to both companies' shareholders and
patients. We look forward to welcoming the GW team to Jazz to build an even
stronger company."
"Over the last two decades, GW
has built an unparalleled global leadership position in cannabinoid science,
including the successful launch of Epidiolex, a breakthrough product within the
field of epilepsy, and a diverse and robust neuroscience pipeline. We believe
that Jazz is an ideal growth partner that is committed to supporting our
commercial efforts, as well as ongoing clinical and research programs,"
said Justin Gover, CEO of GW Pharmaceuticals. "We have a shared vision of
developing and commercializing innovative medicines that address significant
unmet needs in neuroscience and an approach of putting patients first.
Together, we will have an opportunity to reach and impact more patients through
a broader portfolio of neuroscience-focused therapies than ever before."
Jason
Wilson,
cannabis and banking expert at ETF
Managers Group (NYSE:
MJ)
commented on this recent acquisition as well as the recent trends in the
cannabis space saying “Jazz Pharma’s acquisition of GW Pharma, at a significant
premium, demonstrates that pharmaceutical companies are recognizing the value
and future potential of cannabinoid based medicines. It is also another example that the cannabis
industry is continuing to normalize and evolve beyond the traditional
cultivation of flower, with potential well outside of our borders. For investors, the acquisition of GW Pharma
is another reminder that investing in cannabis touches many verticals globally,
requiring a diverse approach beyond traditional cannabis cultivation
companies.”
Mr Wilson
continued to discuss some of the other factors behind the recent rally in
cannabis stocks, such as “domestically, Senate Majority Leader Schumer has
confirmed that cannabis reform legislation will be a key priority in the
current Congress, and that it will include sensible tax and regulatory
oversight at the federal level along with criminal justice reform; Globally,
Mexico recently published its federal medical cannabis regulations, and the UN
voted to remove medical cannabis from its list of dangerous narcotics. These
recent catalysts occurred on the backdrop of strong global cannabis sales
growth in 2020 (2020 global sales are expected to reach approximately $20
billion – an increase of approximately 35% versus 2019 sales of $15 billion)
and suggest that the industry will continue to see strong growth and continued
expansion domestically and globally for the foreseeable future. MJ’s
diversified cannabis portfolio has benefitted from these recent global and
domestic catalysts (up 90%+ in the previous three months, 40%+ YTD), and
remains well positioned to take advantage of what is expected to be one of the
fastest growing global industries over the next decade.”
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps
including Robinhood , Acorn, Stash and
others.
Hear the investor ideas potcast on Spotify
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and
equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to
regulations of each country. Please read Investorideas.com privacy
policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
